Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025
Rhea-AI Summary
Collegium Pharmaceutical (Nasdaq: COLL) announced it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. The company will host a live conference call and webcast at 8:00 a.m. ET following the release.
Conference call dial-in numbers are (877) 407-8037 (U.S.) and (201) 689-8037 (International) referencing the “Collegium Pharmaceutical Q3 2025 Earnings Call.” An audio webcast and a replay will be available from the Investors section of the company website at www.collegiumpharma.com, with the replay posted about two hours after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, COLL declined 0.48%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
STOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.
Conference Call Information
To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q3 2025 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Investor Contacts:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com
Danielle Jesse
Director, Investor Relations
ir@collegiumpharma.com
FAQ
When will Collegium (COLL) report Q3 2025 financial results?
What time is the Collegium (COLL) Q3 2025 earnings call and webcast?
How can investors join the Collegium (COLL) Q3 2025 conference call?
Where can I access the Collegium (COLL) earnings webcast and replay?
Will the Collegium (COLL) earnings webcast be available for replay and when?
